Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases

Table 3 Comparison of anti-S protein antibody titers between treatment groups within each time point of sample extraction

	Pre-third dose		Post-third dose
	FC [95%CI]	p value	FC [95%CI]	p value
Non-biological—not treated or GCs only	0.62 [0.21, 1.90]	0.4059	0.42 [0.12, 1.50]	0.1845
Biological—not treated or GCs only	0.10 [0.03, 0.31]	0.00007	0.14 [0.04, 0.53]	0.0027
Biological—non-biological	0.29 [0.12, 0.72]	0.0072	0.49 [0.17, 1.43]	0.1904
JAKi—non-biological	0.50 [0.13, 1.90]	0.3066	0.37 [0.08, 1.66]	0.1935
JAKi—biological	3.21 [0.89, 11.55]	0.0742	1.15 [0.29, 4.59]	0.8483

Cells show Fold-changes (FC), 95% confidence intervals (CI) and I values of the corresponding comparison. FCs and p values were derived from a mixed-effects linear model where sex, age, rheumatic condition, treatment type, use of glucocorticoids, type of vaccine, sample type (pre- or post-3rd dose) and time from previous dose where included as fixed effects, as well as the interaction between: sex and sample type; treatment and sample type; rheumatic condition and sample type; use of glucocorticoids and sample type; time from second and third vaccine dose and sample type; glucocorticoids use and treatment regimen; and glucorticoids use and rheumatic condition. Individual effects were included as random effects in this model. SLE Systemic Lupus Erythematosus, RA Rheumatoid Arthritis, B27-AS HLA-B27 positive Ankylosing Spondylitis, PSA Psoriatic Arthritis, GCA Giant Cell Arteritis, GCs Glucocorticoids; JAKi JAK inhibitors, GCs Glucocorticoids, FC Fold-Change, 95%CI 95% confidence interval

ISSN: 2047-783X